Are Mangalam Drugs latest results good or bad?

Mangalam Drugs and Organics has reported its financial results for the quarter ending March 2025, which indicate significant challenges for the company. The Profit After Tax (PAT) has fallen to Rs 0.06 crore, representing a substantial decline compared to the average PAT of Rs 2.55 crore over the previous four quarters. This sharp reduction highlights a troubling trend in the company's profitability. Net sales for the quarter were reported at Rs 73.04 crore, which is a decrease from the average net sales of Rs 86.86 crore in the prior four quarters. This figure marks the lowest sales recorded in the last five quarters, suggesting a negative trajectory in the company's financial health. Interest expenses have reached a five-quarter high of Rs 4.03 crore, reflecting an increase in borrowing costs. Additionally, the Earnings per Share (EPS) has dropped to Rs 0.04, indicating reduced earnings for shareholders. Overall, the financial results for Mangalam Drugs and Organics reveal significant operational challenges. The company saw an adjustment in its evaluation, reflecting the current financial difficulties.